Literature DB >> 1448668

Management of brain metastases.

J B Posner1.   

Abstract

Brain metastases are common and often occur in patients whose systemic cancer is quiescent. When brain metastases occur, they considerably decrease the quality of life in patients who otherwise might be functional. An early diagnosis and vigorous treatment of the brain metastasis, while only rarely curative, may lead to a useful remission of the brain symptoms and may both enhance the quality of the patient's life and prolong survival. Patients with known cancer and neurological symptoms should all undergo appropriate diagnostic tests which include either CT scan or magnetic resonance imaging and, if a lesion is found and a definitive diagnosis can not be established, biopsy. Single or solitary brain metastases in patients with good systemic performance status should be strongly considered for surgical extirpation which will both make the diagnosis and deliver definitive treatment to the lesion. Patients with poor systemic performance status and/or multiple brain metastases are candidates for whole brain radiation therapy. Whole brain radiation therapy is also indicated in patients after successful surgical extirpation of a single metastasis. The role of focal radiation therapy and chemotherapy in the treatment of brain metastases is still being evaluated. Preliminary evidence suggests that focal radiation therapy is probably useful for the treatment of relapsed metastases and that chemotherapy may be useful in the primary treatment of small or asymptomatic brain metastases. Appropriate use of therapeutic modalities directed at brain tumors will ameliorate symptoms in most patients and usually increase survival and enhance the quality of the patient's life.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448668

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  56 in total

Review 1.  Radiosurgery in the treatment of brain metastases: critical review regarding complications.

Authors:  Marcos Vinícius Calfat Maldaun; Paulo Henrique Pires Aguiar; Frederick Lang; Dima Suki; David Wildrick; Raymond Sawaya
Journal:  Neurosurg Rev       Date:  2007-10-24       Impact factor: 3.042

Review 2.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

Review 3.  Current management of metastatic brain disease.

Authors:  Tulika Ranjan; Lauren E Abrey
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Angiogenesis, metastasis, and endogenous inhibition.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Distant brain recurrence in patients with five or more newly diagnosed brain metastases treated with focal stereotactic radiotherapy alone.

Authors:  Olivia Claire Barrett; Andrew M McDonald; Jonathan W Thompson; Markus Bredel; Gerald McGwin; Kristen O Riley; John B Fiveash
Journal:  J Radiosurg SBRT       Date:  2017

6.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

7.  Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.

Authors:  Juan JuanYin; Kirsten Tracy; Luhua Zhang; Jeeva Munasinghe; Erik Shapiro; Alan Koretsky; Kathleen Kelly
Journal:  Clin Exp Metastasis       Date:  2009-03-11       Impact factor: 5.150

8.  Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases.

Authors:  David Roberge; Kevin Petrecca; Munir El Refae; Luis Souhami
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

9.  Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model.

Authors:  Cathie G Miller; Nigel W Fraser
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

10.  Clinical analysis of patients who survived for less than 3 months after brain metastatectomy.

Authors:  Young Zoon Kim; Kyu Hong Kim; Joon Soo Kim; Yeong Jin Song; Ki Uk Kim; Hyung Dong Kim
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.